FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: a composition for treating cancer containing (a) a conjugate containing (i) a polypeptide vector containing an amino acid sequence min. 70% identical to AngioPep-2 (SEQ ID NO: 97); and (ii) paclitaxel or a paclitaxel analogue conjugated with the above polypeptide; (b) an optional tonicity agent; (c) a buffer agent; (d) an excipient; (e) a polyoxyethylene ester of fatty acid; and (f) 0.01-8% DMSO (versions), a method for preparing (versions), a method of treating cancer, a container comprising the above composition, and a kit comprising the container with the above composition.
EFFECT: invention differs by the fact that the declared conjugates (eg ANG 1005) may pass through the hematoencephalic barrier, be characterised by high absorption by the targeted cells, manifest higher stability or be removed from the cell in a lesser degree, while the based compositions may be dissolved in an aqueous solution; they differ by stability and the minimal decomposition at temperatures within the range of 40°C and 50°C.
53 cl, 3 dwg, 28 tbl
Title | Year | Author | Number |
---|---|---|---|
ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | 2009 |
|
RU2531591C2 |
POLYPEPTIDE CAPABLE OF OVERCOMING HEMATOENCEPHALIC BARRIER, AND CONJUGATE THEREOF | 2005 |
|
RU2408605C2 |
APROTININ POLYPEPTIDES FOR TRANSPORT OF COMPOUND THROUGH BLOOD-BRAIN BARRIER | 2010 |
|
RU2611193C2 |
ANTIANGIOGENIC COMPOUNDS | 2009 |
|
RU2511420C2 |
MODULATION OF COMPLEMENT ACTIVITY | 2015 |
|
RU2670988C2 |
NOVEL POLYPEPTIDES | 2014 |
|
RU2674604C2 |
INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
COMPLEMENT ACTIVITY MODULATION | 2015 |
|
RU2778514C2 |
VERSIONS OF ALBUMIN | 2010 |
|
RU2607374C2 |
MULTIPLE OLIGONUCLEOTIDE FRAGMENTS ON A PEPTIDE CARRIER | 2015 |
|
RU2739987C2 |
Authors
Dates
2014-06-10—Published
2009-04-20—Filed